Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.

Stantec reports strong third quarter 2025 results, delivering over 17% growth in adjusted earnings per share

Highlights Net revenue of $1.7 billion, an increase of 11.8% compared to Q3 2024Adjusted EBITDA1 increase of 17.8% to $323.4 million and adjusted EBITDA margin1 of 19.0%, a 100 basis point increase ...

Edgewell Personal Care Announces Fourth Quarter and Fiscal 2025 Results; Provides 2026 Outlook

Edgewell Personal Care Company (NYSE: EPC) today announced results for its fourth fiscal quarter 2025 and fiscal year ended September 30, 2025.

Xos Extends Profitability Streak with Strong Q3 2025 Performance and Positive Operating Cash Flow

Delivered 130 units and generated $16.5 million in revenueAchieved 15.3% Gross Margin and a second consecutive quarter of positive free cash flow ...

Edgewell Personal Care Company: Edgewell Personal Care Announces Fourth Quarter and Fiscal 2025 Results; Provides 2026 Outlook

Fourth Quarter Net Sales increased 3.8%, or 2.5% Organic increase Fiscal 2025 Net Sales decreased 1.3%, or 1.3% Organic decrease Fiscal 2025 GAAP EPS $0.53, Adjusted ...